KRAS, KRAS proto-oncogene, GTPase, 3845

N. diseases: 1213; N. variants: 54
Disease: Pancreatic Neoplasm ×
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0030297
Disease: Pancreatic Neoplasm
Pancreatic Neoplasm 		0.700 GeneticVariation disease BEFREE Efforts to model pancreatic cancer in mice have focused on mimicking genetic changes found in the human disease, particularly the activating KRAS mutations that occur in pancreatic tumors and their putative precursors, pancreatic intraepithelial neoplasia (PanIN). 19028876 2008
CUI: C0030297
Disease: Pancreatic Neoplasm
Pancreatic Neoplasm 		0.700 GeneticVariation disease BEFREE Mutation of the K-ras gene is thought to be an early and important event in pancreatic tumor initiation, but the precise role of the mutant K-Ras proteins in neoplastic progression is still unknown. 16257181 2006
CUI: C0030297
Disease: Pancreatic Neoplasm
Pancreatic Neoplasm 		0.700 GeneticVariation disease BEFREE To evaluate its diagnostic efficacy, we performed BCL10 immunohistochemistry and evaluated molecular markers correlated to pancreatic tumor lineages (neuroendocrine markers and a mutation analysis of KRAS and GNAS) using samples from 126 pancreatic tumors (17 ACCs, 24 pancreatic ductal adenocarcinomas, 4 adenosquamous carcinomas, 9 intraductal papillary mucinous neoplasms, 10 mucinous cystic neoplasms, 44 neuroendocrine tumors, 9 serous cystic tumors and 10 solid-pseudopapillary neoplasms). 23530562 2013
CUI: C0030297
Disease: Pancreatic Neoplasm
Pancreatic Neoplasm 		0.700 GeneticVariation disease BEFREE K-ras gene mutation in patients with chronic pencreatitis did not seem to be related to the development of pancreatic neoplasm during the follow-up period, and analysis of K-ras gene mutation seems of little use for diagnosing pancreatic neoplasm in patients with chronic pancreatitis. 9247481 1997
CUI: C0030297
Disease: Pancreatic Neoplasm
Pancreatic Neoplasm 		0.700 GeneticVariation disease BEFREE KRAS mutations are major factors involved in initiation and maintenance of pancreatic tumors. 23565280 2013
CUI: C0030297
Disease: Pancreatic Neoplasm
Pancreatic Neoplasm 		0.700 GeneticVariation disease BEFREE By using the recombinant adenovirus in a mice model system, it was possible to accomplish efficient reversion of the malignant phenotype in human pancreatic tumors with K-ras gene mutation. 14767540 2004
CUI: C0030297
Disease: Pancreatic Neoplasm
Pancreatic Neoplasm 		0.700 GeneticVariation disease BEFREE Mutation at codon 12 of the K-ras gene was found in 25 (81%) of 31 pancreatic tumors, including three G-to-A transitions and 22 G-to-T transversions. 11719088 2002
CUI: C0030297
Disease: Pancreatic Neoplasm
Pancreatic Neoplasm 		0.700 GeneticVariation disease BEFREE Dual Farnesyl and Geranylgeranyl Transferase Inhibitor Thwarts Mutant KRAS-Driven Patient-Derived Pancreatic Tumors. 31227505 2019
CUI: C0030297
Disease: Pancreatic Neoplasm
Pancreatic Neoplasm 		0.700 GeneticVariation disease BEFREE K-ras mutation was detected at high levels (mutant ras genes occupied >2% of all K-ras genes) in 25 of the 38 cases (66%) with pancreatic neoplasm. 12204431 2002
CUI: C0030297
Disease: Pancreatic Neoplasm
Pancreatic Neoplasm 		0.700 AlteredExpression disease BEFREE Knock down of K-RAS resulted in impaired tumor growth in all pancreatic xenograft models tested, demonstrating that K-RAS expression is indeed required for tumor maintenance of K-RAS mutant pancreatic tumors. 22952903 2012
CUI: C0030297
Disease: Pancreatic Neoplasm
Pancreatic Neoplasm 		0.700 Biomarker disease BEFREE PCR-based-SafeSeqS assays were used to identify mutations at codon 12, 13 and 61 of KRAS in the primary pancreatic tumor and to detect ctDNA. 31250894 2019
CUI: C0030297
Disease: Pancreatic Neoplasm
Pancreatic Neoplasm 		0.700 Biomarker disease BEFREE Roles for KRAS in pancreatic tumor development and progression. 23622131 2013
CUI: C0030297
Disease: Pancreatic Neoplasm
Pancreatic Neoplasm 		0.700 GeneticVariation disease BEFREE Overall, the repurposing of decitabine emerged as an intriguing option for treating pancreatic tumors that are addicted to mutant KRAS, thus offering opportunities for improving the arsenal of therapeutics for this extremely deadly disease. 31492820 2019
CUI: C0030297
Disease: Pancreatic Neoplasm
Pancreatic Neoplasm 		0.700 Biomarker disease BEFREE Genetically Engineered Mouse Models of K-Ras-Driven Lung and Pancreatic Tumors: Validation of Therapeutic Targets. 28778964 2018
CUI: C0030297
Disease: Pancreatic Neoplasm
Pancreatic Neoplasm 		0.700 GeneticVariation disease BEFREE Quantitative analysis of K-ras gene mutation in pancreatic tissue obtained by endoscopic ultrasonography-guided fine needle aspiration: clinical utility for diagnosis of pancreatic tumor. 12358243 2002
CUI: C0030297
Disease: Pancreatic Neoplasm
Pancreatic Neoplasm 		0.700 Biomarker disease BEFREE V‑Ki‑ras 2 Kirsten rat sarcoma viral oncogene homolog (KRAS) is one of the most important genes involved in pancreatic neoplasms, and exhibits a high mutation rate in pancreatic ductal adenocarcinomas and pancreatic intraepithelial neoplasia. 29658583 2018
CUI: C0030297
Disease: Pancreatic Neoplasm
Pancreatic Neoplasm 		0.700 GeneticVariation disease BEFREE A recombinant chimeric protein specifically induces mutant KRAS degradation and potently inhibits pancreatic tumor growth. 27322423 2016
CUI: C0030297
Disease: Pancreatic Neoplasm
Pancreatic Neoplasm 		0.700 GeneticVariation disease BEFREE We disrupted Acvr1b specifically in pancreata of mice (Acvr1b(flox/flox);Pdx1-Cre mice) and crossed them with LSL-KRAS(G12D) mice, which express an activated form of KRAS and develop spontaneous pancreatic tumors. 26408346 2016
CUI: C0030297
Disease: Pancreatic Neoplasm
Pancreatic Neoplasm 		0.700 AlteredExpression disease BEFREE Surprisingly, the three enhancers are active in four different pancreatic tumor cell lines that express either normal K-ras gene or mutant K-ras. 19254697 2009
CUI: C0030297
Disease: Pancreatic Neoplasm
Pancreatic Neoplasm 		0.700 GeneticVariation disease BEFREE Eighty-seven genomic alterations were identified in the 23 pancreatic tumor FNAs (average, 3.8 genomic alterations per patient); and the most common genomic alterations were KRAS, TP53, CDKN2A/B, SMAD4, and PTEN. 23893923 2013
CUI: C0030297
Disease: Pancreatic Neoplasm
Pancreatic Neoplasm 		0.700 Biomarker disease BEFREE Loss of IKBKE inhibits the initiation and progression of pancreatic tumors in mice carrying pancreatic-specific KRAS activation. 28069799 2017
CUI: C0030297
Disease: Pancreatic Neoplasm
Pancreatic Neoplasm 		0.700 Biomarker disease BEFREE Furthermore, we identified phosphorylated KRAS in a panel of primary human pancreatic tumors. 24371225 2014
CUI: C0030297
Disease: Pancreatic Neoplasm
Pancreatic Neoplasm 		0.700 GeneticVariation disease BEFREE ERK1/2 inhibitor can suppress growth of KRAS-mutant pancreatic tumors by targeting cancer cell. 31133044 2019
CUI: C0030297
Disease: Pancreatic Neoplasm
Pancreatic Neoplasm 		0.700 AlteredExpression disease BEFREE Stat3, Il6st (encodes gp130), or Trp53 were disrupted, or a mutant form of P53 (P53R172H) or transgenic sgp130 were expressed, in mice that developed pancreatic tumors resulting from expression of activated KRAS (KrasG12D, KC mice). 27003603 2016
CUI: C0030297
Disease: Pancreatic Neoplasm
Pancreatic Neoplasm 		0.700 Biomarker disease BEFREE Loss of Somatostatin Receptor Subtype 2 Promotes Growth of KRAS-Induced Pancreatic Tumors in Mice by Activating PI3K Signaling and Overexpression of CXCL16. 25683115 2015